Want to see MTVA full AI Analyst Report?
MTVA Stock Chart & Stats
$1.40
-$0.13(-5.60%)
At close: 4:00 PM EST
$1.40
-$0.13(-5.60%)
Day’s Range― - ―
52-Week Range$0.97 - $19.02
Previous CloseN/A
Volume36.62K
Average Volume (3M)3.42M
Market Cap
$8.93M
Enterprise Value-$9.77M
Total Cash (Recent Filing)$13.73M
Total Debt (Recent Filing)$194.00K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 18, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.03
Shares Outstanding5,164,370
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit651.50
Enterprise Value/Ebitda0.75
Forecast
1Y Price Target
$14.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Of DA-1726Durable clinical signal: reproducible ~9% weight loss in Phase 1 higher-dose cohorts demonstrates meaningful pharmacologic activity and potential differentiation vs existing GLP-1 drugs. Strong early efficacy supports continued development, partner interest, and value creation in a large obesity market over months.
Intellectual Property And Pipeline BreadthRobust IP and multiple assets raise structural barriers to entry and enable strategic partnering. Licensed global patents for DA-1726 and vanoglipel protect novel mechanisms and support combination strategies across obesity, MASH, and diabetes, expanding addressable markets and long-term strategic optionality.
Capital Access FlexibilityStructured access to equity via an ATM, combined with prior financings, provides a repeatable mechanism to raise incremental funds when needed. This flexibility, together with very low reported debt, preserves financing optionality critical for a pre-revenue biotech advancing clinical programs over the next several quarters.
Bears Say
Pre-Revenue Status And Ongoing LossesStructural limitation: without commercial revenue the company must rely on funding to sustain R&D. Persistent multi‑million dollar losses mean value depends entirely on clinical progress and external financing, increasing execution risk if trials or endpoints underperform or timelines slip.
High And Persistent Cash BurnSustained negative operating cash flow indicates the business is not self-funding. Continued high burn consumes cash reserves and narrows runway absent new financing, which can force dilutive raises or slow program timelines, impairing long-term development continuity and partner negotiations.
Shrinking Equity And Dilution RiskMaterial decline in equity over recent years reflects repeated capital raises and losses, creating structural dilution risk. Combined with active ATM and equity plan actions, ongoing financing needs are likely to pressure ownership and could complicate long-term shareholder returns absent successful clinical milestones.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.97 and its highest was $19.02 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $8.93M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on May 14, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.743 by -$0.047.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.82.
How many shares outstanding does MetaVia have?
MetaVia has 5,164,370 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.743. Following the earnings report the stock price went down -6.723%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
MTVA Stock 12 Month Forecast
Average Price Target
$14.00
▲(900.00% Upside)
Technical Analysis
Ownership Overview
3.77% Insiders
0.27% Mutual Funds
0.19% Other Institutional Investors
95.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---